Brother Enterprises (SZ:002562)2019-10-23 16:00Financial Performance - Net profit attributable to shareholders was ¥19,855,360.10, a significant increase of 303.86% year-on-year[7]. - Operating revenue for the reporting period was ¥270,787,798.01, down 14.20% compared to the same period last year[7]. - Basic earnings per share were ¥0.02, an increase of 277.07% compared to the same period last year[7]. - The company reported a significant increase in other receivables, rising to ¥532,082,041.53 from ¥216,387,051.96, an increase of about 146.5%[33]. - Net profit decreased by 74.54% to CNY 19,223,671.13, attributed to a decline in vitamin prices and increased operating expenses[15]. - The total comprehensive income for Q3 2019 was CNY 20,388,125.40, recovering from a loss of CNY 10,148,434.86 in the same quarter last year[40]. - The company reported a comprehensive income total of ¥18,016,634.38, down 76.5% from ¥76,560,125.95 in the previous period[48]. - The company experienced a net loss of ¥8,472,991.77 in the third quarter, compared to a net loss of ¥21,739,662.18 in the previous period[44]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥21,086,858.89, a decrease of 123.37% year-on-year[7]. - Cash and cash equivalents decreased by 66.37% to CNY 190,496,615.42 due to increased payments for goods and equipment[15]. - The net cash flow from operating activities was negative CNY 111,028,442.76, a decrease from a positive CNY 281,297,383.28 in the previous year[54]. - Cash inflow from operating activities totaled CNY 848,232,118.89, down from CNY 1,081,747,190.69 year-over-year[52]. - The cash outflow for purchasing goods and services was CNY 681,970,674.76, which increased from CNY 483,330,082.60 in the previous year[52]. - The cash flow from financing activities showed a net inflow of CNY 149,067,391.77, contrasting with a net outflow of CNY 110,589,843.36 in the previous year[55]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,703,247,621.36, an increase of 3.39% compared to the end of the previous year[7]. - Total current assets decreased to ¥1,150,760,400.22 from ¥1,442,911,202.64, a decline of approximately 20.2% year-over-year[29]. - Total non-current assets rose to ¥2,552,487,221.14 from ¥2,139,075,545.46, an increase of about 19.3%[29]. - Total liabilities increased to ¥1,410,695,615.88 from ¥1,323,115,707.05, reflecting a growth of approximately 6.6%[30]. - The company's total liabilities increased to CNY 824,310,653.74 from CNY 679,741,830.68, reflecting a rise of 21.3%[36]. - Total equity attributable to shareholders increased to ¥2,292,552,005.48 from ¥2,258,871,041.05, a rise of about 1.5%[31]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,041[11]. - The top two shareholders, Qian Zhida and Qian Zhiming, held 28.54% and 23.74% of shares respectively, both with pledged shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. - The company repurchased 6,791,240 shares, accounting for 0.7529% of the total share capital, with a total payment of CNY 30,000,260.48[17]. Expenses - Management expenses increased by 52.51% to CNY 141,111,175.80, mainly due to costs associated with the second phase of the pharmaceutical project[15]. - Financial expenses increased by 44.19% to CNY 21,495,612.34, primarily due to increased exchange losses[15]. - Research and development expenses for Q3 2019 were CNY 16,067,279.00, a decrease of 19.4% compared to CNY 19,942,354.35 in the same period last year[38]. - Research and development expenses were ¥43,859,788.95, down 18.1% from ¥53,546,717.31 in the previous period[45]. Future Outlook - The company expects a net profit increase of over 50% for 2019, with an estimated range of CNY 43.63 million to CNY 52.36 million[19]. - The company plans to focus on market expansion and new product development to drive future growth[36].